Europe
The FDA and CDC will soon decide on Pfizer-BioNTech’s request for an Emergency Use Authorization for the booster shot for their COVID-19 vaccine.
The strategic collaboration entails a $180 million equity investment into Owkin and a total payment of $90 million over the next three years, in addition to milestone-based fees to be determined later.
Biopharma and life sciences companies from across the globe provide updates. Belgium-based Galapagos NV won European approval for Jyseleca for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
While COVID-19 appears to be surging again in the U.S. and Europe, the government is spending billions to acquire antibody and antiviral therapies and edging toward vaccination boosters.
Investors are falling in with these biotech companies, dropping dollars to fuel their work for the latest advancement in life sciences.
Respiratory Syncytial Virus has been around for a very long period now. But there was no vaccine yet. But, here’s the first vaccine for RSV to shape the future.
Los Angeles-based ACELYRIN, Inc. announced a quarter-million dollars in Series B financing Tuesday morning, along with a splashy licensing deal.
It’s been a week of gained and lost opportunities after two large biopharmaceutical firms announced changes to their staff rosters.
It was another busy week for clinical trial news. Here’s a look.
The total revenue for the quarter was $9.74 billion, a leap of 47%. The COVID-19 vaccine, Vaxzevria, only contributed 1% to the company’s profit.
PRESS RELEASES